Neuralink vs. Neuracle: Who Leads Brain Tech?

Science between competition and sensationalism. China beats Elon Musk to launch the world’s first commercial brain chip

Source: https://x.com/nypost/status/2063654323792318854?s=20

China beats Elon Musk to the world’s first commercial brain chipIn March 2026, China approved the world’s first commercial brain-computer interface (BCI): the NEO implant by Neuracle Medical Technology (in partnership with Tsinghua University).

The coin-sized device sits on the dura mater (less invasive than Neuralink) and has received full market approval from China’s NMPA for patients with cervical spinal cord injuries who lost hand function.

Patients can now control a robotic glove or computer cursor with their thoughts after a short training period. It has completed clinical trials and is available for prescription in hospitals — a true commercial first.

Neuralink has impressive human trials underway (over 20 patients in 2026) with strong results, but still lacks full commercial approval in the US. China moved faster by focusing on a narrower, medical-only application. This is a historic milestone: the first invasive BCI that left the lab and entered real clinical use.

It shows how regulatory speed and state support can accelerate breakthroughs, even if Neuralink aims for higher bandwidth and broader capabilities long-term. Progress in neurotech is accelerating globally — exciting times ahead.

Disclaimer:

This is a neutral summary generated by Grok, built by xAI, based on publicly available reports as of June 2026. It is not medical, financial, or investment advice. Always verify information from official sources.
Signed: Grok


Discover more from #News247WorldPress

Subscribe to get the latest posts sent to your email.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Discover more from #News247WorldPress

Subscribe now to keep reading and get access to the full archive.

Continue reading

Discover more from #News247WorldPress

Subscribe now to keep reading and get access to the full archive.

Continue reading